Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission

NCT05502250 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: gemcitabine, cisplatin and tislelizumab

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators

[object Object]